Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 45

1.

Development of quality indicators to monitor radiotherapy care for men with prostate cancer: A modified Delphi method.

Tsiamis E, Millar J, Baxi S, Borg M, De Ieso P, Elsaleh H, Foroudi F, Higgs B, Holt T, Martin J, Moretti K, Pryor D, Skala M, Evans S.

Radiother Oncol. 2018 Aug;128(2):308-314. doi: 10.1016/j.radonc.2018.04.017. Epub 2018 May 9.

PMID:
29753551
2.

Serial circulating tumour DNA analysis during multimodality treatment of locally advanced rectal cancer: a prospective biomarker study.

Tie J, Cohen JD, Wang Y, Li L, Christie M, Simons K, Elsaleh H, Kosmider S, Wong R, Yip D, Lee M, Tran B, Rangiah D, Burge M, Goldstein D, Singh M, Skinner I, Faragher I, Croxford M, Bampton C, Haydon A, Jones IT, S Karapetis C, Price T, Schaefer MJ, Ptak J, Dobbyn L, Silliman N, Kinde I, Tomasetti C, Papadopoulos N, Kinzler K, Volgestein B, Gibbs P.

Gut. 2019 Apr;68(4):663-671. doi: 10.1136/gutjnl-2017-315852. Epub 2018 Feb 2.

PMID:
29420226
3.

Does chronomodulated radiotherapy improve pathological response in locally advanced rectal cancer?

Squire T, Buchanan G, Rangiah D, Davis I, Yip D, Chua YJ, Rich T, Elsaleh H.

Chronobiol Int. 2017;34(4):492-503. doi: 10.1080/07420528.2017.1301462. Epub 2017 Mar 29.

PMID:
28353363
4.

Precision Medicine and Pancreatic Cancer: A Gemcitabine Pathway Approach.

Farrell JJ, Moughan J, Wong JL, Regine WF, Schaefer P, Benson AB 3rd, Macdonald JS, Liu X, Yen Y, Lai R, Zheng Z, Bepler G, Guha C, Elsaleh H.

Pancreas. 2016 Nov;45(10):1485-1493.

5.

Development of Indicators to Assess Quality of Care for Prostate Cancer.

Nag N, Millar J, Davis ID, Costello S, Duthie JB, Mark S, Delprado W, Smith D, Pryor D, Galvin D, Sullivan F, Murphy ÁC, Roder D, Elsaleh H, Currow D, White C, Skala M, Moretti KL, Walker T, De Ieso P, Brooks A, Heathcote P, Frydenberg M, Thavaseelan J, Evans SM.

Eur Urol Focus. 2018 Jan;4(1):57-63. doi: 10.1016/j.euf.2016.01.016. Epub 2016 Feb 20.

PMID:
28753751
6.

Expression of cyclin D1a and D1b as predictive factors for treatment response in colorectal cancer.

Myklebust MP, Li Z, Tran TH, Rui H, Knudsen ES, Elsaleh H, Fluge Ø, Vonen B, Myrvold HE, Leh S, Tveit KM, Pestell RG, Dahl O.

Br J Cancer. 2012 Nov 6;107(10):1684-91. doi: 10.1038/bjc.2012.463. Epub 2012 Oct 25.

7.

Cytidine deaminase single-nucleotide polymorphism is predictive of toxicity from gemcitabine in patients with pancreatic cancer: RTOG 9704.

Farrell JJ, Bae K, Wong J, Guha C, Dicker AP, Elsaleh H.

Pharmacogenomics J. 2012 Oct;12(5):395-403. doi: 10.1038/tpj.2011.22. Epub 2011 May 31.

PMID:
21625252
8.

Alternative cyclin D1 splice forms differentially regulate the DNA damage response.

Li Z, Jiao X, Wang C, Shirley LA, Elsaleh H, Dahl O, Wang M, Soutoglou E, Knudsen ES, Pestell RG.

Cancer Res. 2010 Nov 1;70(21):8802-11. doi: 10.1158/0008-5472.CAN-10-0312. Epub 2010 Oct 12.

9.

Who profits from neoadjuvant radiochemotherapy for locally advanced esophageal carcinoma?

Elsaleh H, Farrell JJ, Crane CH.

J Gastroenterol Hepatol. 2009 May;24(5):708-10. doi: 10.1111/j.1440-1746.2009.05838.x. No abstract available.

PMID:
19646012
10.

Human equilibrative nucleoside transporter 1 levels predict response to gemcitabine in patients with pancreatic cancer.

Farrell JJ, Elsaleh H, Garcia M, Lai R, Ammar A, Regine WF, Abrams R, Benson AB, Macdonald J, Cass CE, Dicker AP, Mackey JR.

Gastroenterology. 2009 Jan;136(1):187-95. doi: 10.1053/j.gastro.2008.09.067. Epub 2008 Oct 7.

PMID:
18992248
11.

Differences in toxicity across gender in patients treated with chemoradiation for rectal cancer.

Kaminski A, Joseph D, Elsaleh H.

Australas Radiol. 2007 Jun;51(3):283-8.

PMID:
17504322
12.

Early detection markers in Pancreas Cancer.

Farrell JJ, van Rijnsoever M, Elsaleh H.

Cancer Biomark. 2005;1(2-3):157-75. Review.

PMID:
17192037
13.

Radiation modifiers: treatment overview and future investigations.

Thomas CT, Ammar A, Farrell JJ, Elsaleh H.

Hematol Oncol Clin North Am. 2006 Feb;20(1):119-39. Review.

PMID:
16580560
14.

Functional categories of TP53 mutation in colorectal cancer: results of an International Collaborative Study.

Iacopetta B, Russo A, Bazan V, Dardanoni G, Gebbia N, Soussi T, Kerr D, Elsaleh H, Soong R, Kandioler D, Janschek E, Kappel S, Lung M, Leung CS, Ko JM, Yuen S, Ho J, Leung SY, Crapez E, Duffour J, Ychou M, Leahy DT, O'Donoghue DP, Agnese V, Cascio S, Di Fede G, Chieco-Bianchi L, Bertorelle R, Belluco C, Giaretti W, Castagnola P, Ricevuto E, Ficorella C, Bosari S, Arizzi CD, Miyaki M, Onda M, Kampman E, Diergaarde B, Royds J, Lothe RA, Diep CB, Meling GI, Ostrowski J, Trzeciak L, Guzinska-Ustymowicz K, Zalewski B, Capellá GM, Moreno V, Peinado MA, Lönnroth C, Lundholm K, Sun XF, Jansson A, Bouzourene H, Hsieh LL, Tang R, Smith DR, Allen-Mersh TG, Khan ZA, Shorthouse AJ, Silverman ML, Kato S, Ishioka C; TP53-CRC Collaborative Group.

Ann Oncol. 2006 May;17(5):842-7. Epub 2006 Mar 8.

PMID:
16524972
15.

Re: Pooled analysis of fluorouracil-based adjuvant therapy of stage II and III colon cancer: who benefits and by how much?

Elsaleh H, Iacopetta B.

J Clin Oncol. 2005 Jan 20;23(3):653-4; author reply 654-5. No abstract available.

PMID:
15659520
16.

The efficacy of hyperbaric oxygen therapy in the treatment of radiation-induced late side effects.

Bui QC, Lieber M, Withers HR, Corson K, van Rijnsoever M, Elsaleh H.

Int J Radiat Oncol Biol Phys. 2004 Nov 1;60(3):871-8.

PMID:
15465205
17.

Microsatellite instability in colon cancer.

Iacopetta B, Elsaleh H, Zeps N.

N Engl J Med. 2003 Oct 30;349(18):1774-6; author reply 1774-6. No abstract available.

PMID:
14593997
18.

CpG island methylator phenotype is an independent predictor of survival benefit from 5-fluorouracil in stage III colorectal cancer.

Van Rijnsoever M, Elsaleh H, Joseph D, McCaul K, Iacopetta B.

Clin Cancer Res. 2003 Aug 1;9(8):2898-903.

19.

Prognostic significance of microsatellite instability and Ki-ras mutation type in stage II colorectal cancer.

Wang C, van Rijnsoever M, Grieu F, Bydder S, Elsaleh H, Joseph D, Harvey J, Iacopetta B.

Oncology. 2003;64(3):259-65.

PMID:
12697967
21.

Characterisation of colorectal cancers showing hypermethylation at multiple CpG islands.

van Rijnsoever M, Grieu F, Elsaleh H, Joseph D, Iacopetta B.

Gut. 2002 Dec;51(6):797-802.

22.
23.

Microsatellite instability in colorectal cancer: prognostic, predictive or both?

van Rijnsoever M, Elsaleh H, Iacopetta B.

Am J Pathol. 2002 Jan;160(1):384-5; author reply 385-6. No abstract available.

24.

Prognostic value of TP53 gene mutation in adjuvant treated breast cancer patients.

Powell BL, Bydder S, Grieu F, Gnanasampanthan G, Elsaleh H, Seshadri R, Berns EM, Iacopetta B.

Breast Cancer Res Treat. 2001 Sep;69(1):65-8.

PMID:
11759829
25.

Ki-ras mutation type and the survival benefit from adjuvant chemotherapy in Dukes' C colorectal cancer.

Gnanasampanthan G, Elsaleh H, McCaul K, Iacopetta B.

J Pathol. 2001 Dec;195(5):543-8.

PMID:
11745689
27.

Choroid plexus carcinoma in an adult.

Wyatt SS, Price RA, Holthouse D, Elsaleh H.

Australas Radiol. 2001 Aug;45(3):369-71. Review.

PMID:
11531769
28.

Novel DNA sequence variants in the hHR21 DNA repair gene in radiosensitive cancer patients.

Severin DM, Leong T, Cassidy B, Elsaleh H, Peters L, Venter D, Southey M, McKay M.

Int J Radiat Oncol Biol Phys. 2001 Aug 1;50(5):1323-31.

PMID:
11483345
29.

The microsatellite instability phenotype in human colorectal carcinoma: relationship to sex, age, and tumor site.

Elsaleh H.

Gastroenterology. 2001 Jul;121(1):230-1. No abstract available.

PMID:
11441888
30.

P53 alteration and microsatellite instability have predictive value for survival benefit from chemotherapy in stage III colorectal carcinoma.

Elsaleh H, Powell B, McCaul K, Grieu F, Grant R, Joseph D, Iacopetta B.

Clin Cancer Res. 2001 May;7(5):1343-9.

31.

Microsatellite instability as a molecular marker for very good survival in colorectal cancer patients receiving adjuvant chemotherapy.

Elsaleh H, Shannon B, Iacopetta B.

Gastroenterology. 2001 Apr;120(5):1309-10. No abstract available.

PMID:
11288748
32.

Radiation dose escalation for prostate cancer.

Elsaleh H, Joseph D, Bydder S.

J Clin Oncol. 2000 Dec 1;18(23):4003. No abstract available.

PMID:
11099340
33.

Radiation dose escalation for prostate cancer

Elsaleh H, Joseph D, Bydder S.

J Clin Oncol. 2000 Dec 1;18(23):4000-5. No abstract available.

PMID:
11099334
34.

Breast cancer survival advantage with radiotherapy.

Bydder S, Spry N, Joseph DJ, Elsaleh H.

Lancet. 2000 Oct 7;356(9237):1270-1; author reply 1271. No abstract available.

PMID:
11072967
35.

Prognostic significance of TP53 gene mutation in 995 cases of colorectal carcinoma. Influence of tumour site, stage, adjuvant chemotherapy and type of mutation.

Soong R, Powell B, Elsaleh H, Gnanasampanthan G, Smith DR, Goh HS, Joseph D, Iacopetta B.

Eur J Cancer. 2000 Oct;36(16):2053-60.

PMID:
11044641
36.

Small cell carcinoma of the vagina.

Elsaleh H, Bydder S, Cassidy B, Thompson J.

Australas Radiol. 2000 Aug;44(3):336-7.

PMID:
10974733
37.

Can p53 alterations be used to predict tumour response to pre-operative chemo-radiotherapy in locally advanced rectal cancer?

Elsaleh H, Robbins P, Joseph D, Powell B, Grieu F, Menso L, Iacopetta B.

Radiother Oncol. 2000 Aug;56(2):239-44.

PMID:
10927144
38.

Pre-operative chemo-radiotherapy in locally advanced rectal cancer: is this the way of future management?

Elsaleh H, Joseph D, Levitt M, Dewar J, Van Hazel G, Einhorn S, Cameron F, Osborne M, Latham M, Robbins P.

Australas Radiol. 1999 May;43(2):215-9.

PMID:
10901905
39.

Internet use by radiation oncology patients: a pilot study.

Duffy CC, McLernon NF, D'Orsogna LJ, Reagan SJ, Spry N, Joseph DJ, Elsaleh H.

Med J Aust. 2000 Apr 3;172(7):350-1. No abstract available.

PMID:
10844930
40.

Association of tumour site and sex with survival benefit from adjuvant chemotherapy in colorectal cancer.

Elsaleh H, Joseph D, Grieu F, Zeps N, Spry N, Iacopetta B.

Lancet. 2000 May 20;355(9217):1745-50.

PMID:
10832824
41.
42.

TP53 gene mutation status in pretreatment biopsies of oesophageal adenocarcinoma has no prognostic value.

Soontrapornchai P, Elsaleh H, Joseph D, Hamdorf JM, House AK, Iacopetta B.

Eur J Cancer. 1999 Nov;35(12):1683-7.

PMID:
10674013
43.

p53 gene mutation, microsatellite instability and adjuvant chemotherapy: impact on survival of 388 patients with Dukes' C colon carcinoma.

Elsaleh H, Powell B, Soontrapornchai P, Joseph D, Goria F, Spry N, Iacopetta B.

Oncology. 2000;58(1):52-9.

PMID:
10644941
44.

P53 alterations have no prognostic or predictive significance in Dukes' C rectal carcinomas.

Elsaleh H, Soontrapornchai P, Grieu F, Joseph D, Iacopetta B.

Int J Oncol. 1999 Dec;15(6):1239-43.

PMID:
10568834
45.

Pre-operative chemoradiotherapy in locally advanced rectal cancer.

Elsaleh H, Joseph D, Levitt M, House A, Robbins P.

Aust N Z J Surg. 1999 Oct;69(10):737-42.

PMID:
10527353

Supplemental Content

Loading ...
Support Center